Robert Griffin
Concepts (704)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 37 | 2024 | 1233 | 5.250 |
Why?
| Hyperthermia, Induced | 17 | 2019 | 116 | 3.690 |
Why?
| Mammary Neoplasms, Experimental | 12 | 2015 | 121 | 3.300 |
Why?
| Radiotherapy | 10 | 2021 | 124 | 3.020 |
Why?
| Air Pollutants | 13 | 2024 | 64 | 2.970 |
Why?
| Gold | 9 | 2023 | 129 | 2.630 |
Why?
| Bystander Effect | 5 | 2024 | 25 | 2.130 |
Why?
| Mice | 75 | 2024 | 5658 | 2.120 |
Why?
| Radiation-Sensitizing Agents | 11 | 2023 | 51 | 2.080 |
Why?
| Animals | 100 | 2024 | 13100 | 2.040 |
Why?
| Nanostructures | 5 | 2023 | 45 | 1.870 |
Why?
| Cell Line, Tumor | 39 | 2024 | 1388 | 1.760 |
Why?
| Exosomes | 7 | 2022 | 47 | 1.700 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 182 | 1.600 |
Why?
| Phototherapy | 5 | 2022 | 42 | 1.590 |
Why?
| Radiation Tolerance | 9 | 2020 | 83 | 1.540 |
Why?
| Metal Nanoparticles | 4 | 2023 | 80 | 1.510 |
Why?
| Blood Vessels | 9 | 2020 | 71 | 1.490 |
Why?
| Nanoparticles | 6 | 2022 | 151 | 1.460 |
Why?
| Neoplasms, Experimental | 6 | 2020 | 111 | 1.440 |
Why?
| Galectin 1 | 4 | 2017 | 20 | 1.410 |
Why?
| Environmental Monitoring | 8 | 2024 | 66 | 1.400 |
Why?
| Aerosols | 10 | 2023 | 74 | 1.390 |
Why?
| Lung Neoplasms | 9 | 2024 | 600 | 1.380 |
Why?
| Oxygen | 12 | 2020 | 323 | 1.350 |
Why?
| Polyethylene Glycols | 4 | 2022 | 85 | 1.320 |
Why?
| Air Pollution | 3 | 2024 | 44 | 1.280 |
Why?
| Particulate Matter | 5 | 2024 | 54 | 1.260 |
Why?
| Carcinoma, Squamous Cell | 6 | 2019 | 330 | 1.240 |
Why?
| Combined Modality Therapy | 17 | 2022 | 638 | 1.130 |
Why?
| Endothelial Cells | 7 | 2021 | 256 | 1.120 |
Why?
| Humans | 107 | 2024 | 49898 | 1.100 |
Why?
| Tumor Necrosis Factor-alpha | 8 | 2019 | 388 | 1.050 |
Why?
| Wind | 2 | 2024 | 6 | 1.030 |
Why?
| Sulfates | 2 | 2023 | 24 | 1.020 |
Why?
| Neovascularization, Pathologic | 9 | 2021 | 153 | 1.020 |
Why?
| Fibrosarcoma | 7 | 2019 | 15 | 1.010 |
Why?
| Apoptosis | 10 | 2024 | 1092 | 1.000 |
Why?
| Antineoplastic Agents | 13 | 2024 | 1175 | 0.940 |
Why?
| Liposomes | 2 | 2022 | 52 | 0.920 |
Why?
| Oxygen Consumption | 4 | 2020 | 188 | 0.910 |
Why?
| Peptides | 10 | 2022 | 220 | 0.910 |
Why?
| Ozone | 6 | 2022 | 19 | 0.890 |
Why?
| Benzeneacetamides | 2 | 2024 | 12 | 0.880 |
Why?
| Glutaminase | 2 | 2024 | 18 | 0.880 |
Why?
| Fluorescent Dyes | 5 | 2022 | 105 | 0.870 |
Why?
| Cell Communication | 3 | 2021 | 69 | 0.870 |
Why?
| Mice, Inbred BALB C | 8 | 2020 | 296 | 0.860 |
Why?
| Proteins | 6 | 2010 | 347 | 0.850 |
Why?
| Pyrimidines | 10 | 2024 | 192 | 0.810 |
Why?
| Indocyanine Green | 2 | 2013 | 34 | 0.810 |
Why?
| Neoplastic Cells, Circulating | 3 | 2017 | 74 | 0.780 |
Why?
| Protein Kinase Inhibitors | 6 | 2024 | 205 | 0.760 |
Why?
| Cell Survival | 16 | 2024 | 590 | 0.730 |
Why?
| Thiadiazoles | 3 | 2024 | 18 | 0.730 |
Why?
| Flow Cytometry | 5 | 2017 | 470 | 0.730 |
Why?
| Radiotherapy, Intensity-Modulated | 4 | 2022 | 174 | 0.710 |
Why?
| Radiosurgery | 6 | 2020 | 120 | 0.710 |
Why?
| Antioxidants | 2 | 2020 | 234 | 0.690 |
Why?
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 153 | 0.690 |
Why?
| Radiation-Protective Agents | 1 | 2020 | 72 | 0.670 |
Why?
| Radiation Dosage | 2 | 2020 | 157 | 0.670 |
Why?
| Immunotherapy | 2 | 2021 | 235 | 0.670 |
Why?
| Radiotherapy Dosage | 6 | 2022 | 246 | 0.660 |
Why?
| Radiotherapy Planning, Computer-Assisted | 6 | 2023 | 250 | 0.650 |
Why?
| Models, Theoretical | 7 | 2015 | 172 | 0.650 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 281 | 0.640 |
Why?
| Epigenesis, Genetic | 2 | 2019 | 370 | 0.620 |
Why?
| Drug Delivery Systems | 2 | 2022 | 143 | 0.620 |
Why?
| Aniline Compounds | 5 | 2024 | 42 | 0.620 |
Why?
| Information Dissemination | 2 | 2016 | 79 | 0.620 |
Why?
| Arsenicals | 3 | 2007 | 14 | 0.610 |
Why?
| Oxides | 3 | 2007 | 18 | 0.600 |
Why?
| Cell Proliferation | 12 | 2024 | 986 | 0.600 |
Why?
| Molecular Imaging | 2 | 2015 | 54 | 0.590 |
Why?
| Uncertainty | 2 | 2022 | 43 | 0.590 |
Why?
| Disease Models, Animal | 11 | 2020 | 1411 | 0.580 |
Why?
| Xenograft Model Antitumor Assays | 13 | 2021 | 212 | 0.580 |
Why?
| Bone and Bones | 2 | 2012 | 473 | 0.570 |
Why?
| Female | 35 | 2021 | 26560 | 0.570 |
Why?
| Gamma Rays | 2 | 2020 | 48 | 0.570 |
Why?
| Oxidation-Reduction | 5 | 2023 | 315 | 0.570 |
Why?
| Radiotherapy, Conformal | 2 | 2019 | 53 | 0.560 |
Why?
| Pneumonia, Viral | 1 | 2020 | 170 | 0.560 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 121 | 0.550 |
Why?
| Coronavirus Infections | 1 | 2020 | 179 | 0.550 |
Why?
| Science | 1 | 2016 | 17 | 0.550 |
Why?
| Mice, Nude | 12 | 2019 | 252 | 0.550 |
Why?
| Radiobiology | 5 | 2023 | 21 | 0.540 |
Why?
| Mouth Neoplasms | 4 | 2015 | 20 | 0.520 |
Why?
| Enzyme Inhibitors | 7 | 2024 | 378 | 0.520 |
Why?
| Texas | 7 | 2024 | 142 | 0.500 |
Why?
| Pandemics | 1 | 2020 | 566 | 0.500 |
Why?
| Cell Hypoxia | 6 | 2015 | 82 | 0.490 |
Why?
| Carcinoma | 2 | 2013 | 139 | 0.470 |
Why?
| Exons | 3 | 2024 | 96 | 0.470 |
Why?
| Solanum tuberosum | 1 | 2014 | 5 | 0.460 |
Why?
| Laser Therapy | 2 | 2013 | 84 | 0.460 |
Why?
| Sanitation | 1 | 2014 | 16 | 0.460 |
Why?
| Radiation Oncology | 3 | 2024 | 23 | 0.460 |
Why?
| Bone Marrow Neoplasms | 1 | 2013 | 12 | 0.450 |
Why?
| Coloring Agents | 2 | 2013 | 67 | 0.450 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 824 | 0.440 |
Why?
| Chemokines | 1 | 2013 | 75 | 0.440 |
Why?
| Spectrum Analysis, Raman | 3 | 2019 | 54 | 0.440 |
Why?
| Plasmodium falciparum | 2 | 2024 | 19 | 0.440 |
Why?
| Malaria, Falciparum | 2 | 2024 | 14 | 0.430 |
Why?
| Tumor Microenvironment | 7 | 2022 | 221 | 0.430 |
Why?
| Infrared Rays | 2 | 2019 | 25 | 0.430 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 462 | 0.420 |
Why?
| Signal Transduction | 8 | 2021 | 1608 | 0.420 |
Why?
| Indoles | 4 | 2024 | 273 | 0.410 |
Why?
| Cell Death | 7 | 2019 | 174 | 0.400 |
Why?
| Adult Stem Cells | 1 | 2012 | 10 | 0.400 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 457 | 0.400 |
Why?
| Conservation of Natural Resources | 3 | 2017 | 30 | 0.400 |
Why?
| DNA Damage | 5 | 2019 | 298 | 0.390 |
Why?
| Lignin | 1 | 2011 | 2 | 0.390 |
Why?
| Environmental Pollution | 1 | 2011 | 11 | 0.390 |
Why?
| Bone Neoplasms | 2 | 2011 | 178 | 0.390 |
Why?
| Time Factors | 12 | 2017 | 2891 | 0.390 |
Why?
| Ecosystem | 3 | 2017 | 64 | 0.380 |
Why?
| Mice, Inbred C3H | 9 | 2015 | 82 | 0.380 |
Why?
| Models, Biological | 6 | 2018 | 719 | 0.370 |
Why?
| Dose-Response Relationship, Radiation | 10 | 2020 | 183 | 0.370 |
Why?
| Photochemical Processes | 1 | 2010 | 9 | 0.370 |
Why?
| Phenols | 1 | 2011 | 79 | 0.360 |
Why?
| Saliva | 3 | 2007 | 55 | 0.360 |
Why?
| Photons | 2 | 2020 | 19 | 0.360 |
Why?
| Cytokines | 1 | 2013 | 607 | 0.360 |
Why?
| Cell Line | 6 | 2021 | 1010 | 0.350 |
Why?
| Breast Neoplasms | 6 | 2017 | 1183 | 0.350 |
Why?
| Melanoma, Experimental | 2 | 2021 | 40 | 0.350 |
Why?
| Methionine | 3 | 2020 | 133 | 0.340 |
Why?
| Rats | 11 | 2022 | 3273 | 0.340 |
Why?
| Mutagenesis, Insertional | 3 | 2024 | 24 | 0.340 |
Why?
| Radiation Injuries | 3 | 2020 | 110 | 0.330 |
Why?
| Volatile Organic Compounds | 2 | 2022 | 5 | 0.330 |
Why?
| Hydroxyl Radical | 2 | 2010 | 7 | 0.320 |
Why?
| Glutamine | 3 | 2024 | 169 | 0.320 |
Why?
| Atmosphere | 4 | 2019 | 9 | 0.320 |
Why?
| Receptor, erbB-2 | 5 | 2016 | 74 | 0.320 |
Why?
| Reactive Oxygen Species | 3 | 2024 | 405 | 0.320 |
Why?
| Radiation | 2 | 2020 | 15 | 0.310 |
Why?
| Weightlessness Simulation | 2 | 2020 | 19 | 0.310 |
Why?
| Drug Carriers | 2 | 2013 | 69 | 0.310 |
Why?
| Precancerous Conditions | 2 | 2010 | 83 | 0.300 |
Why?
| History, 20th Century | 3 | 2020 | 95 | 0.300 |
Why?
| Caspase Inhibitors | 1 | 2008 | 16 | 0.300 |
Why?
| Cell Membrane Permeability | 1 | 2008 | 28 | 0.300 |
Why?
| Mice, SCID | 3 | 2024 | 173 | 0.300 |
Why?
| China | 3 | 2023 | 87 | 0.300 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 30 | 0.300 |
Why?
| Forecasting | 4 | 2020 | 146 | 0.290 |
Why?
| Carbon Radioisotopes | 2 | 2024 | 53 | 0.290 |
Why?
| Nanomedicine | 2 | 2024 | 20 | 0.290 |
Why?
| Male | 20 | 2024 | 25437 | 0.290 |
Why?
| Freezing | 2 | 2004 | 16 | 0.290 |
Why?
| Caspases | 1 | 2007 | 104 | 0.290 |
Why?
| Adenocarcinoma | 1 | 2011 | 401 | 0.280 |
Why?
| Vascular Neoplasms | 1 | 2007 | 17 | 0.280 |
Why?
| Nanotubes, Carbon | 2 | 2017 | 68 | 0.270 |
Why?
| Radiotherapy, Image-Guided | 2 | 2016 | 23 | 0.270 |
Why?
| Risk Assessment | 3 | 2017 | 1254 | 0.270 |
Why?
| Glutathione | 2 | 2019 | 296 | 0.270 |
Why?
| Melanoma | 2 | 2020 | 281 | 0.260 |
Why?
| Microscopy, Fluorescence | 3 | 2018 | 164 | 0.260 |
Why?
| Cryotherapy | 2 | 2011 | 12 | 0.260 |
Why?
| Organs at Risk | 3 | 2022 | 70 | 0.250 |
Why?
| Hindlimb | 2 | 2004 | 30 | 0.250 |
Why?
| Tyrosine-tRNA Ligase | 1 | 2024 | 1 | 0.250 |
Why?
| Administration, Oral | 6 | 2024 | 433 | 0.240 |
Why?
| Hydrogen-Ion Concentration | 5 | 2005 | 168 | 0.240 |
Why?
| Ovarian Neoplasms | 2 | 2008 | 450 | 0.240 |
Why?
| Antimalarials | 1 | 2024 | 24 | 0.240 |
Why?
| Doxorubicin | 2 | 2024 | 233 | 0.240 |
Why?
| Cell Culture Techniques | 2 | 2019 | 97 | 0.230 |
Why?
| Disease Progression | 4 | 2019 | 820 | 0.230 |
Why?
| Oxidants, Photochemical | 1 | 2004 | 3 | 0.230 |
Why?
| Endocytosis | 1 | 2024 | 61 | 0.230 |
Why?
| Smog | 1 | 2004 | 5 | 0.230 |
Why?
| Porphyrins | 1 | 2023 | 10 | 0.230 |
Why?
| Proteomics | 4 | 2021 | 292 | 0.230 |
Why?
| Oxidants | 1 | 2004 | 54 | 0.230 |
Why?
| Clinical Trials as Topic | 3 | 2023 | 466 | 0.230 |
Why?
| Nitroimidazoles | 2 | 2015 | 15 | 0.230 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2017 | 183 | 0.230 |
Why?
| Radiometry | 2 | 2016 | 123 | 0.220 |
Why?
| Photochemotherapy | 1 | 2023 | 33 | 0.220 |
Why?
| Sulfur Oxides | 1 | 2023 | 1 | 0.220 |
Why?
| Gulf of Mexico | 1 | 2023 | 5 | 0.220 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2021 | 116 | 0.220 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2008 | 51 | 0.220 |
Why?
| Carcinoma, Hepatocellular | 2 | 2023 | 194 | 0.220 |
Why?
| Partial Pressure | 3 | 2011 | 14 | 0.210 |
Why?
| Environmental Exposure | 2 | 2022 | 200 | 0.210 |
Why?
| Halogens | 1 | 2022 | 3 | 0.210 |
Why?
| Phosphatidylethanolamines | 1 | 2022 | 10 | 0.210 |
Why?
| Organic Anion Transporters | 1 | 2022 | 1 | 0.210 |
Why?
| Lipid Bilayers | 1 | 2022 | 12 | 0.210 |
Why?
| Tumor Burden | 3 | 2010 | 131 | 0.210 |
Why?
| Bile | 1 | 2022 | 23 | 0.210 |
Why?
| Chloral Hydrate | 1 | 2022 | 18 | 0.210 |
Why?
| Parasites | 1 | 2002 | 3 | 0.210 |
Why?
| Water Pollution | 1 | 2002 | 8 | 0.210 |
Why?
| Tissue Distribution | 1 | 2022 | 163 | 0.200 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 9 | 0.200 |
Why?
| Receptors, Growth Factor | 1 | 2002 | 7 | 0.200 |
Why?
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 6 | 0.200 |
Why?
| Protein Binding | 5 | 2020 | 656 | 0.200 |
Why?
| X-Rays | 3 | 2016 | 55 | 0.200 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 3 | 2007 | 13 | 0.200 |
Why?
| Biological Transport | 2 | 2021 | 170 | 0.200 |
Why?
| Naphthoquinones | 3 | 2007 | 10 | 0.200 |
Why?
| Protons | 1 | 2022 | 67 | 0.200 |
Why?
| Liver Neoplasms | 2 | 2023 | 329 | 0.200 |
Why?
| Cholesterol | 1 | 2022 | 148 | 0.200 |
Why?
| Pyrroles | 1 | 2002 | 68 | 0.190 |
Why?
| Boron Compounds | 1 | 2021 | 19 | 0.190 |
Why?
| Floods | 1 | 2021 | 2 | 0.190 |
Why?
| Nucleotides, Cyclic | 1 | 2021 | 4 | 0.190 |
Why?
| Neoplasm Proteins | 3 | 2017 | 321 | 0.190 |
Why?
| Spheroids, Cellular | 3 | 2019 | 24 | 0.190 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.190 |
Why?
| Optical Imaging | 2 | 2020 | 23 | 0.190 |
Why?
| Endosomes | 1 | 2021 | 33 | 0.190 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2021 | 19 | 0.190 |
Why?
| Radiation, Ionizing | 4 | 2018 | 97 | 0.180 |
Why?
| Cells, Cultured | 4 | 2020 | 1587 | 0.180 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 55 | 0.180 |
Why?
| Proteasome Inhibitors | 1 | 2021 | 104 | 0.180 |
Why?
| Proton Therapy | 1 | 2020 | 11 | 0.180 |
Why?
| Cell Transformation, Neoplastic | 3 | 2018 | 181 | 0.180 |
Why?
| Spectrum Analysis | 1 | 2020 | 71 | 0.180 |
Why?
| Chronic Pain | 1 | 2023 | 171 | 0.180 |
Why?
| Thymus Gland | 1 | 2020 | 42 | 0.180 |
Why?
| History, 21st Century | 1 | 2020 | 56 | 0.180 |
Why?
| Neural Stem Cells | 1 | 2020 | 26 | 0.180 |
Why?
| Cell Differentiation | 2 | 2020 | 649 | 0.170 |
Why?
| Adenosine Triphosphate | 1 | 2021 | 231 | 0.170 |
Why?
| Public Health | 1 | 2002 | 205 | 0.170 |
Why?
| Heavy Ion Radiotherapy | 1 | 2019 | 2 | 0.170 |
Why?
| Receptor, TIE-2 | 2 | 2017 | 16 | 0.170 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 9 | 0.170 |
Why?
| Spleen | 1 | 2020 | 170 | 0.170 |
Why?
| Calixarenes | 2 | 2017 | 9 | 0.170 |
Why?
| Autoantibodies | 1 | 2020 | 114 | 0.170 |
Why?
| Societies, Medical | 1 | 2020 | 177 | 0.170 |
Why?
| Whole-Body Irradiation | 1 | 2020 | 129 | 0.170 |
Why?
| Cone-Beam Computed Tomography | 2 | 2016 | 33 | 0.170 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 139 | 0.170 |
Why?
| Interleukin-6 | 2 | 2020 | 265 | 0.170 |
Why?
| Preservation, Biological | 1 | 2018 | 8 | 0.160 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 75 | 0.160 |
Why?
| Drug Evaluation, Preclinical | 3 | 2015 | 145 | 0.160 |
Why?
| Membrane Proteins | 1 | 2021 | 347 | 0.160 |
Why?
| Environmental Pollutants | 1 | 2020 | 92 | 0.160 |
Why?
| Ephrin-B2 | 1 | 2018 | 5 | 0.160 |
Why?
| Paracrine Communication | 1 | 2018 | 12 | 0.160 |
Why?
| Astrocytes | 1 | 2020 | 146 | 0.160 |
Why?
| Cystic Fibrosis | 1 | 2021 | 151 | 0.160 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.160 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 124 | 0.160 |
Why?
| Myocytes, Cardiac | 1 | 2019 | 122 | 0.160 |
Why?
| Treatment Outcome | 5 | 2020 | 5176 | 0.160 |
Why?
| Lipopolysaccharides | 1 | 2019 | 195 | 0.160 |
Why?
| Microinjections | 1 | 2018 | 33 | 0.150 |
Why?
| Biological Assay | 1 | 2018 | 46 | 0.150 |
Why?
| Calibration | 1 | 2018 | 57 | 0.150 |
Why?
| Galectins | 1 | 2018 | 5 | 0.150 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2018 | 4 | 0.150 |
Why?
| Prostatic Neoplasms | 2 | 2013 | 391 | 0.150 |
Why?
| Nucleosides | 1 | 2018 | 5 | 0.150 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 100 | 0.150 |
Why?
| Indazoles | 1 | 2018 | 44 | 0.150 |
Why?
| Gastrointestinal Tract | 1 | 2019 | 101 | 0.150 |
Why?
| Erythrocyte Membrane | 1 | 2017 | 14 | 0.150 |
Why?
| California | 4 | 2010 | 87 | 0.150 |
Why?
| Oceans and Seas | 1 | 2017 | 24 | 0.150 |
Why?
| Particle Size | 2 | 2024 | 79 | 0.150 |
Why?
| MicroRNAs | 1 | 2021 | 347 | 0.150 |
Why?
| Structure-Activity Relationship | 7 | 2021 | 394 | 0.150 |
Why?
| Scavenger Receptors, Class E | 1 | 2019 | 203 | 0.140 |
Why?
| Histocompatibility Antigens Class II | 1 | 2017 | 37 | 0.140 |
Why?
| Models, Molecular | 4 | 2021 | 334 | 0.140 |
Why?
| Small Molecule Libraries | 1 | 2018 | 67 | 0.140 |
Why?
| Epitope Mapping | 1 | 2017 | 6 | 0.140 |
Why?
| Vehicle Emissions | 1 | 2017 | 10 | 0.140 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 22 | 0.140 |
Why?
| Bacteria | 1 | 2018 | 219 | 0.140 |
Why?
| Myocardial Infarction | 1 | 2021 | 391 | 0.140 |
Why?
| Silver | 1 | 2017 | 48 | 0.140 |
Why?
| Ammonia | 1 | 2017 | 72 | 0.140 |
Why?
| Pyridazines | 2 | 2008 | 11 | 0.140 |
Why?
| Sulfonamides | 1 | 2018 | 125 | 0.140 |
Why?
| Biomass | 1 | 2016 | 18 | 0.140 |
Why?
| Random Allocation | 2 | 2015 | 285 | 0.140 |
Why?
| Epithelial Cells | 1 | 2018 | 209 | 0.140 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 994 | 0.140 |
Why?
| Mice, Inbred Strains | 3 | 2013 | 160 | 0.130 |
Why?
| Antibodies | 1 | 2017 | 151 | 0.130 |
Why?
| Dendritic Cells | 1 | 2017 | 133 | 0.130 |
Why?
| Radiation Protection | 1 | 2016 | 46 | 0.130 |
Why?
| Extraterrestrial Environment | 1 | 2016 | 7 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2007 | 84 | 0.130 |
Why?
| Chemistry, Organic | 2 | 2019 | 2 | 0.130 |
Why?
| Cyclonic Storms | 1 | 2015 | 6 | 0.130 |
Why?
| Organ Specificity | 1 | 2016 | 106 | 0.130 |
Why?
| Extracellular Fluid | 1 | 2015 | 14 | 0.130 |
Why?
| Tomography, Spiral Computed | 1 | 2016 | 56 | 0.130 |
Why?
| Microbubbles | 1 | 2015 | 25 | 0.130 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2016 | 90 | 0.130 |
Why?
| Multiple Myeloma | 1 | 2010 | 2915 | 0.130 |
Why?
| Organ Sparing Treatments | 1 | 2016 | 55 | 0.130 |
Why?
| Sulfuric Acids | 1 | 2015 | 8 | 0.120 |
Why?
| Cell Count | 1 | 2015 | 147 | 0.120 |
Why?
| Stromal Cells | 1 | 2015 | 72 | 0.120 |
Why?
| Pressure | 1 | 2015 | 105 | 0.120 |
Why?
| Rabbits | 3 | 2010 | 375 | 0.120 |
Why?
| Biomedical Research | 1 | 2018 | 241 | 0.120 |
Why?
| Necrosis | 3 | 2013 | 175 | 0.120 |
Why?
| Tandem Mass Spectrometry | 3 | 2017 | 227 | 0.120 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 152 | 0.120 |
Why?
| Carbon Dioxide | 2 | 2005 | 94 | 0.120 |
Why?
| Image Processing, Computer-Assisted | 1 | 2016 | 242 | 0.120 |
Why?
| Cisplatin | 2 | 2024 | 275 | 0.120 |
Why?
| Brain | 2 | 2020 | 1310 | 0.120 |
Why?
| Mexico | 1 | 2014 | 35 | 0.120 |
Why?
| Hot Temperature | 3 | 2013 | 204 | 0.120 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2017 | 482 | 0.110 |
Why?
| United States | 4 | 2019 | 4878 | 0.110 |
Why?
| Contrast Media | 1 | 2015 | 186 | 0.110 |
Why?
| Animals, Inbred Strains | 1 | 2013 | 5 | 0.110 |
Why?
| DNA Methylation | 1 | 2018 | 544 | 0.110 |
Why?
| Stress, Psychological | 1 | 2015 | 258 | 0.110 |
Why?
| Ultrasonography | 1 | 2015 | 429 | 0.110 |
Why?
| Nanoconjugates | 1 | 2013 | 1 | 0.110 |
Why?
| Ions | 2 | 2024 | 31 | 0.110 |
Why?
| Food, Genetically Modified | 1 | 2013 | 1 | 0.110 |
Why?
| Food Labeling | 1 | 2013 | 6 | 0.110 |
Why?
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 4 | 0.110 |
Why?
| Societies, Scientific | 1 | 2013 | 14 | 0.110 |
Why?
| Antigen-Presenting Cells | 1 | 2013 | 24 | 0.110 |
Why?
| Nanospheres | 1 | 2013 | 8 | 0.110 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 181 | 0.110 |
Why?
| Nanotechnology | 1 | 2013 | 36 | 0.110 |
Why?
| Nutrition Policy | 1 | 2013 | 38 | 0.100 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2013 | 40 | 0.100 |
Why?
| Gene Expression Profiling | 2 | 2017 | 1028 | 0.100 |
Why?
| Mice, Inbred C57BL | 4 | 2020 | 1777 | 0.100 |
Why?
| Linear Models | 1 | 2013 | 274 | 0.100 |
Why?
| Blotting, Western | 1 | 2013 | 587 | 0.100 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 579 | 0.100 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.100 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 409 | 0.100 |
Why?
| Glucose | 2 | 2011 | 337 | 0.100 |
Why?
| RNA, Messenger | 2 | 2013 | 1099 | 0.100 |
Why?
| Surface Plasmon Resonance | 3 | 2017 | 22 | 0.100 |
Why?
| North Carolina | 2 | 2022 | 53 | 0.100 |
Why?
| Gold Colloid | 2 | 2011 | 2 | 0.100 |
Why?
| Acids | 1 | 2011 | 11 | 0.100 |
Why?
| Isomerism | 1 | 2011 | 22 | 0.100 |
Why?
| Gene Expression Regulation | 3 | 2021 | 964 | 0.100 |
Why?
| Copper | 1 | 2011 | 43 | 0.090 |
Why?
| Feces | 2 | 2024 | 131 | 0.090 |
Why?
| Injections, Intravenous | 1 | 2011 | 135 | 0.090 |
Why?
| Aldehydes | 1 | 2011 | 82 | 0.090 |
Why?
| Immunohistochemistry | 2 | 2020 | 972 | 0.090 |
Why?
| Acenaphthenes | 1 | 2010 | 1 | 0.090 |
Why?
| Nitrogen Oxides | 1 | 2010 | 3 | 0.090 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2024 | 131 | 0.090 |
Why?
| Positron-Emission Tomography | 1 | 2012 | 286 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2013 | 328 | 0.090 |
Why?
| Myosins | 1 | 2010 | 17 | 0.090 |
Why?
| Middle Aged | 5 | 2024 | 12285 | 0.090 |
Why?
| Bone Transplantation | 1 | 2010 | 46 | 0.090 |
Why?
| Isoxazoles | 1 | 2009 | 14 | 0.090 |
Why?
| Nitrous Acid | 1 | 2009 | 1 | 0.090 |
Why?
| Free Radicals | 1 | 2009 | 28 | 0.090 |
Why?
| Actins | 1 | 2010 | 115 | 0.090 |
Why?
| Abdomen | 1 | 2010 | 75 | 0.080 |
Why?
| Adult | 5 | 2024 | 13346 | 0.080 |
Why?
| Acetylcysteine | 1 | 2010 | 103 | 0.080 |
Why?
| Microcirculation | 1 | 2010 | 71 | 0.080 |
Why?
| Naphthalenes | 1 | 2010 | 117 | 0.080 |
Why?
| Protein Transport | 1 | 2010 | 183 | 0.080 |
Why?
| Formaldehyde | 1 | 2009 | 50 | 0.080 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2009 | 53 | 0.080 |
Why?
| Glycolysis | 2 | 2021 | 68 | 0.080 |
Why?
| Coculture Techniques | 2 | 2020 | 143 | 0.080 |
Why?
| Chemotherapy, Adjuvant | 2 | 2016 | 121 | 0.080 |
Why?
| Prospective Studies | 3 | 2023 | 2345 | 0.080 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2009 | 37 | 0.080 |
Why?
| Glycogen Synthase Kinase 3 | 2 | 2008 | 20 | 0.080 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 11 | 0.080 |
Why?
| Growth Inhibitors | 2 | 2009 | 27 | 0.080 |
Why?
| Nerve Tissue Proteins | 2 | 2020 | 192 | 0.080 |
Why?
| Methotrexate | 1 | 2009 | 72 | 0.080 |
Why?
| Up-Regulation | 2 | 2007 | 446 | 0.080 |
Why?
| STAT3 Transcription Factor | 2 | 2020 | 80 | 0.080 |
Why?
| Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 27 | 0.080 |
Why?
| Drinking | 2 | 2020 | 38 | 0.080 |
Why?
| Insulin-Like Growth Factor I | 1 | 2009 | 138 | 0.080 |
Why?
| Alkynes | 1 | 2008 | 5 | 0.080 |
Why?
| Pyrrolidines | 1 | 2008 | 67 | 0.080 |
Why?
| HEK293 Cells | 2 | 2020 | 216 | 0.080 |
Why?
| Cytotoxins | 1 | 2008 | 15 | 0.080 |
Why?
| Regional Blood Flow | 2 | 2005 | 106 | 0.080 |
Why?
| Cryosurgery | 2 | 2011 | 35 | 0.080 |
Why?
| Chemical Fractionation | 1 | 2007 | 16 | 0.070 |
Why?
| Drug Synergism | 2 | 2005 | 152 | 0.070 |
Why?
| Fluorescence | 2 | 2018 | 41 | 0.070 |
Why?
| Oxidative Stress | 1 | 2012 | 759 | 0.070 |
Why?
| Toxicity Tests | 1 | 2008 | 54 | 0.070 |
Why?
| Skin | 2 | 2009 | 415 | 0.070 |
Why?
| Cost-Benefit Analysis | 2 | 2021 | 269 | 0.070 |
Why?
| Computer Simulation | 3 | 2016 | 281 | 0.070 |
Why?
| Enzyme Activation | 2 | 2005 | 272 | 0.070 |
Why?
| In Situ Nick-End Labeling | 2 | 2004 | 52 | 0.070 |
Why?
| Histones | 2 | 2020 | 295 | 0.070 |
Why?
| Hearing Loss, Sensorineural | 1 | 2008 | 76 | 0.070 |
Why?
| Sesquiterpenes | 1 | 2008 | 88 | 0.070 |
Why?
| Sulfides | 2 | 2018 | 28 | 0.070 |
Why?
| Neurons | 2 | 2020 | 455 | 0.070 |
Why?
| Angiopoietin-2 | 2 | 2017 | 15 | 0.070 |
Why?
| Angiopoietin-1 | 2 | 2017 | 16 | 0.070 |
Why?
| Concept Formation | 1 | 2006 | 12 | 0.070 |
Why?
| Fibroblast Growth Factor 2 | 2 | 2017 | 35 | 0.070 |
Why?
| Interleukin-2 | 1 | 2006 | 70 | 0.070 |
Why?
| Interleukin-8 | 1 | 2006 | 85 | 0.070 |
Why?
| Lasers | 2 | 2019 | 107 | 0.070 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2017 | 86 | 0.070 |
Why?
| Temperature | 3 | 2018 | 163 | 0.070 |
Why?
| Sarcoma | 1 | 2007 | 65 | 0.070 |
Why?
| Mice, Inbred A | 2 | 2003 | 15 | 0.060 |
Why?
| Electrophoresis | 1 | 2005 | 16 | 0.060 |
Why?
| Feasibility Studies | 2 | 2022 | 382 | 0.060 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 858 | 0.060 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 223 | 0.060 |
Why?
| Neoadjuvant Therapy | 2 | 2017 | 118 | 0.060 |
Why?
| Carbon | 1 | 2005 | 55 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2006 | 127 | 0.060 |
Why?
| Colorectal Neoplasms | 2 | 2006 | 253 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 60 | 0.060 |
Why?
| Alkanes | 1 | 2005 | 8 | 0.060 |
Why?
| Neoplasm Staging | 2 | 2019 | 749 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 137 | 0.060 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 71 | 0.060 |
Why?
| Niacinamide | 1 | 2005 | 23 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 167 | 0.060 |
Why?
| Transplantation, Heterologous | 2 | 2021 | 75 | 0.060 |
Why?
| Protozoan Proteins | 1 | 2024 | 32 | 0.060 |
Why?
| Young Adult | 2 | 2024 | 4029 | 0.060 |
Why?
| Organelles | 1 | 2024 | 18 | 0.060 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 626 | 0.060 |
Why?
| Rats, Inbred F344 | 1 | 2005 | 196 | 0.060 |
Why?
| Kidney Diseases | 1 | 2007 | 211 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 4 | 2009 | 1354 | 0.060 |
Why?
| Administration, Inhalation | 1 | 2005 | 111 | 0.060 |
Why?
| MCF-7 Cells | 1 | 2024 | 62 | 0.060 |
Why?
| Amines | 1 | 2004 | 39 | 0.060 |
Why?
| Lichen Planus, Oral | 1 | 2004 | 1 | 0.060 |
Why?
| Materials Testing | 1 | 2024 | 56 | 0.060 |
Why?
| Leukoplakia, Oral | 1 | 2004 | 6 | 0.060 |
Why?
| Drug Combinations | 2 | 2018 | 126 | 0.060 |
Why?
| Photochemistry | 1 | 2004 | 16 | 0.060 |
Why?
| Hydrocarbons | 1 | 2004 | 5 | 0.060 |
Why?
| Buthionine Sulfoximine | 1 | 2024 | 13 | 0.060 |
Why?
| Photoacoustic Techniques | 2 | 2016 | 71 | 0.060 |
Why?
| Cities | 2 | 2017 | 17 | 0.060 |
Why?
| Binding Sites | 2 | 2021 | 378 | 0.060 |
Why?
| Cations | 1 | 2023 | 10 | 0.060 |
Why?
| Biological Availability | 1 | 2024 | 99 | 0.060 |
Why?
| Monoterpenes | 1 | 2003 | 3 | 0.060 |
Why?
| Carboplatin | 1 | 2024 | 51 | 0.060 |
Why?
| Biocompatible Materials | 1 | 2024 | 68 | 0.060 |
Why?
| Phosphorylation | 3 | 2017 | 526 | 0.060 |
Why?
| Antibiotics, Antineoplastic | 1 | 2024 | 77 | 0.060 |
Why?
| Photosensitizing Agents | 1 | 2023 | 19 | 0.060 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 193 | 0.060 |
Why?
| Mass Spectrometry | 2 | 2019 | 283 | 0.060 |
Why?
| Multicenter Studies as Topic | 1 | 2023 | 89 | 0.060 |
Why?
| Organic Chemicals | 1 | 2003 | 14 | 0.060 |
Why?
| Sphingomyelin Phosphodiesterase | 1 | 2003 | 11 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 32 | 0.050 |
Why?
| Hepatitis B virus | 1 | 2023 | 26 | 0.050 |
Why?
| Aged | 3 | 2021 | 9447 | 0.050 |
Why?
| Prognosis | 2 | 2009 | 1956 | 0.050 |
Why?
| DNA-Binding Proteins | 1 | 2006 | 424 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2005 | 251 | 0.050 |
Why?
| G2 Phase | 1 | 2003 | 13 | 0.050 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 30 | 0.050 |
Why?
| Quinazolines | 1 | 2003 | 32 | 0.050 |
Why?
| Mammary Neoplasms, Animal | 1 | 2003 | 35 | 0.050 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2004 | 213 | 0.050 |
Why?
| Anions | 1 | 2022 | 7 | 0.050 |
Why?
| Consensus | 1 | 2023 | 155 | 0.050 |
Why?
| Analysis of Variance | 1 | 2004 | 552 | 0.050 |
Why?
| Interferons | 1 | 2022 | 38 | 0.050 |
Why?
| Acetone | 1 | 2022 | 7 | 0.050 |
Why?
| Rifampin | 1 | 2022 | 62 | 0.050 |
Why?
| Polyphosphates | 1 | 2022 | 2 | 0.050 |
Why?
| Inositol | 1 | 2022 | 19 | 0.050 |
Why?
| Heating | 1 | 2022 | 6 | 0.050 |
Why?
| Hepatocytes | 1 | 2023 | 179 | 0.050 |
Why?
| Pain Measurement | 1 | 2023 | 246 | 0.050 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 22 | 0.050 |
Why?
| Propionates | 1 | 2002 | 22 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2022 | 1182 | 0.050 |
Why?
| Demography | 1 | 2022 | 93 | 0.050 |
Why?
| Pain Management | 1 | 2023 | 164 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 6 | 0.050 |
Why?
| Protein Isoforms | 1 | 2022 | 118 | 0.050 |
Why?
| Estuaries | 1 | 2021 | 1 | 0.050 |
Why?
| Hydrodynamics | 1 | 2021 | 7 | 0.050 |
Why?
| Bays | 1 | 2021 | 2 | 0.050 |
Why?
| San Francisco | 1 | 2021 | 12 | 0.050 |
Why?
| Income | 1 | 2022 | 101 | 0.050 |
Why?
| Drug Resistance, Neoplasm | 1 | 2024 | 314 | 0.050 |
Why?
| Models, Economic | 1 | 2021 | 17 | 0.050 |
Why?
| Catalytic Domain | 1 | 2021 | 57 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 94 | 0.050 |
Why?
| Protein Structure, Tertiary | 2 | 2017 | 249 | 0.050 |
Why?
| Analgesics, Opioid | 1 | 2007 | 554 | 0.050 |
Why?
| Cricetinae | 1 | 2021 | 211 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 294 | 0.050 |
Why?
| Half-Life | 1 | 2021 | 85 | 0.050 |
Why?
| Phosphates | 1 | 2021 | 46 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2021 | 70 | 0.050 |
Why?
| Molecular Docking Simulation | 1 | 2021 | 72 | 0.050 |
Why?
| Bayes Theorem | 1 | 2021 | 105 | 0.050 |
Why?
| Micronucleus Tests | 1 | 2020 | 6 | 0.050 |
Why?
| ROC Curve | 1 | 2021 | 225 | 0.050 |
Why?
| Cell Line, Transformed | 1 | 2021 | 73 | 0.050 |
Why?
| Software | 2 | 2016 | 274 | 0.050 |
Why?
| Catecholamines | 1 | 2020 | 45 | 0.050 |
Why?
| Limbic Encephalitis | 1 | 2020 | 2 | 0.040 |
Why?
| Elastin | 1 | 2020 | 23 | 0.040 |
Why?
| Monte Carlo Method | 1 | 2020 | 86 | 0.040 |
Why?
| Primary Cell Culture | 1 | 2020 | 61 | 0.040 |
Why?
| ADAM Proteins | 1 | 2020 | 20 | 0.040 |
Why?
| Epitopes | 1 | 2020 | 59 | 0.040 |
Why?
| Autoantigens | 1 | 2020 | 50 | 0.040 |
Why?
| Antiviral Agents | 1 | 2021 | 168 | 0.040 |
Why?
| HeLa Cells | 1 | 2020 | 257 | 0.040 |
Why?
| Cytoprotection | 1 | 2019 | 34 | 0.040 |
Why?
| Facility Design and Construction | 1 | 2019 | 3 | 0.040 |
Why?
| Endothelium | 1 | 2019 | 37 | 0.040 |
Why?
| Energy Intake | 1 | 2020 | 169 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 61 | 0.040 |
Why?
| Glioma | 1 | 2020 | 76 | 0.040 |
Why?
| Stress, Physiological | 1 | 2020 | 173 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 55 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2002 | 209 | 0.040 |
Why?
| Swine | 2 | 2011 | 396 | 0.040 |
Why?
| Skin Neoplasms | 1 | 2004 | 487 | 0.040 |
Why?
| Diffusion Chambers, Culture | 1 | 2018 | 7 | 0.040 |
Why?
| Culture Media, Serum-Free | 1 | 2018 | 15 | 0.040 |
Why?
| Specimen Handling | 1 | 2018 | 54 | 0.040 |
Why?
| Culture Media, Conditioned | 1 | 2018 | 48 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2004 | 2175 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2018 | 36 | 0.040 |
Why?
| Laminin | 1 | 2018 | 19 | 0.040 |
Why?
| Program Development | 1 | 2019 | 162 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 4 | 0.040 |
Why?
| Dextrans | 1 | 2018 | 18 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 54 | 0.040 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 35 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 512 | 0.040 |
Why?
| NAD | 1 | 2018 | 42 | 0.040 |
Why?
| Surface Properties | 1 | 2018 | 72 | 0.040 |
Why?
| Hippocampus | 1 | 2020 | 219 | 0.040 |
Why?
| Autophagy | 1 | 2019 | 165 | 0.040 |
Why?
| Proteoglycans | 1 | 2018 | 81 | 0.040 |
Why?
| Imides | 1 | 2018 | 1 | 0.040 |
Why?
| Mid-Atlantic Region | 1 | 2017 | 6 | 0.040 |
Why?
| New England | 1 | 2017 | 10 | 0.040 |
Why?
| Human Activities | 1 | 2017 | 4 | 0.040 |
Why?
| Carbohydrates | 1 | 2018 | 40 | 0.040 |
Why?
| Macaca fascicularis | 1 | 2017 | 10 | 0.040 |
Why?
| Caco-2 Cells | 1 | 2017 | 26 | 0.040 |
Why?
| Ubiquitin | 1 | 2018 | 45 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2018 | 111 | 0.040 |
Why?
| Cooperative Behavior | 1 | 2019 | 226 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2018 | 96 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2018 | 235 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 197 | 0.040 |
Why?
| Phagocytosis | 1 | 2017 | 49 | 0.040 |
Why?
| Cell Movement | 1 | 2018 | 245 | 0.040 |
Why?
| Nanotubes | 1 | 2017 | 27 | 0.040 |
Why?
| Inflammation | 1 | 2021 | 603 | 0.040 |
Why?
| Drug Interactions | 1 | 2017 | 209 | 0.040 |
Why?
| Collagen | 1 | 2018 | 208 | 0.040 |
Why?
| Cohort Studies | 1 | 2021 | 1403 | 0.040 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2017 | 46 | 0.030 |
Why?
| Cricetulus | 1 | 2017 | 107 | 0.030 |
Why?
| Pyrazoles | 1 | 2018 | 111 | 0.030 |
Why?
| CHO Cells | 1 | 2017 | 121 | 0.030 |
Why?
| Gene Frequency | 1 | 2017 | 95 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 380 | 0.030 |
Why?
| DNA Repair | 1 | 2018 | 185 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2017 | 225 | 0.030 |
Why?
| Fires | 1 | 2016 | 13 | 0.030 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 9 | 0.030 |
Why?
| Taxoids | 1 | 2016 | 37 | 0.030 |
Why?
| Interleukin-1alpha | 1 | 2016 | 11 | 0.030 |
Why?
| Platelet-Derived Growth Factor | 1 | 2016 | 23 | 0.030 |
Why?
| Diet | 1 | 2020 | 553 | 0.030 |
Why?
| Receptors, Progesterone | 1 | 2016 | 63 | 0.030 |
Why?
| Hindlimb Suspension | 1 | 2016 | 37 | 0.030 |
Why?
| Wetlands | 1 | 2015 | 2 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 385 | 0.030 |
Why?
| Particle Accelerators | 1 | 2016 | 51 | 0.030 |
Why?
| Dicumarol | 2 | 2005 | 3 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2016 | 163 | 0.030 |
Why?
| Receptors, Estrogen | 1 | 2016 | 130 | 0.030 |
Why?
| Ecology | 1 | 2015 | 17 | 0.030 |
Why?
| Carbonic Anhydrases | 1 | 2015 | 3 | 0.030 |
Why?
| Energy Metabolism | 1 | 2018 | 282 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 293 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2015 | 58 | 0.030 |
Why?
| Genotype | 1 | 2017 | 538 | 0.030 |
Why?
| Sulfur Dioxide | 1 | 2015 | 3 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2016 | 70 | 0.030 |
Why?
| Public Policy | 1 | 2015 | 38 | 0.030 |
Why?
| Norepinephrine | 1 | 2015 | 113 | 0.030 |
Why?
| Models, Animal | 1 | 2016 | 227 | 0.030 |
Why?
| Mice, Knockout | 1 | 2017 | 835 | 0.030 |
Why?
| Epinephrine | 1 | 2015 | 97 | 0.030 |
Why?
| Risk | 1 | 2015 | 314 | 0.030 |
Why?
| Weight Gain | 1 | 2016 | 230 | 0.030 |
Why?
| Feeding Behavior | 1 | 2016 | 177 | 0.030 |
Why?
| Aged, 80 and over | 1 | 2021 | 3136 | 0.030 |
Why?
| Inhibitory Concentration 50 | 2 | 2004 | 71 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 742 | 0.030 |
Why?
| Culture Media | 2 | 2004 | 94 | 0.030 |
Why?
| Glucocorticoids | 1 | 2015 | 229 | 0.030 |
Why?
| Models, Immunological | 1 | 2013 | 8 | 0.030 |
Why?
| Bone Resorption | 1 | 2016 | 297 | 0.030 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 30 | 0.030 |
Why?
| Protein Structure, Secondary | 1 | 2013 | 71 | 0.030 |
Why?
| Chronic Disease | 1 | 2015 | 565 | 0.030 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2013 | 66 | 0.030 |
Why?
| Decision Making | 1 | 2015 | 273 | 0.030 |
Why?
| Light | 1 | 2013 | 70 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2016 | 1578 | 0.020 |
Why?
| Mutation | 1 | 2018 | 1292 | 0.020 |
Why?
| Computer-Aided Design | 1 | 2011 | 21 | 0.020 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2011 | 3 | 0.020 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 46 | 0.020 |
Why?
| Phantoms, Imaging | 1 | 2011 | 121 | 0.020 |
Why?
| Equipment Design | 1 | 2011 | 286 | 0.020 |
Why?
| Volatilization | 1 | 2010 | 4 | 0.020 |
Why?
| Leukocyte Count | 1 | 2010 | 71 | 0.020 |
Why?
| Solvents | 1 | 2010 | 29 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2016 | 769 | 0.020 |
Why?
| Geography | 1 | 2010 | 61 | 0.020 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2009 | 31 | 0.020 |
Why?
| Air | 1 | 2009 | 23 | 0.020 |
Why?
| Amides | 1 | 2009 | 36 | 0.020 |
Why?
| Retrospective Studies | 1 | 2022 | 6123 | 0.020 |
Why?
| Dogs | 1 | 2009 | 185 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 67 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2009 | 20 | 0.020 |
Why?
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 29 | 0.020 |
Why?
| Thermal Conductivity | 1 | 2009 | 7 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Binding, Competitive | 1 | 2009 | 94 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2010 | 326 | 0.020 |
Why?
| Child | 1 | 2021 | 6844 | 0.020 |
Why?
| Pharmacokinetics | 1 | 2008 | 16 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 225 | 0.020 |
Why?
| Guinea Pigs | 1 | 2008 | 75 | 0.020 |
Why?
| Drug Design | 1 | 2009 | 119 | 0.020 |
Why?
| Isatin | 1 | 2008 | 1 | 0.020 |
Why?
| Bone Marrow | 1 | 2010 | 351 | 0.020 |
Why?
| Auditory Threshold | 1 | 2008 | 48 | 0.020 |
Why?
| Probability | 1 | 2008 | 163 | 0.020 |
Why?
| Weight Loss | 1 | 2010 | 241 | 0.020 |
Why?
| Glycosylphosphatidylinositols | 1 | 2007 | 32 | 0.020 |
Why?
| Crystallography, X-Ray | 1 | 2008 | 148 | 0.020 |
Why?
| Recurrence | 1 | 2009 | 658 | 0.020 |
Why?
| Rubidium | 1 | 2006 | 4 | 0.020 |
Why?
| Isoelectric Point | 1 | 2005 | 4 | 0.020 |
Why?
| Isoelectric Focusing | 1 | 2005 | 8 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 953 | 0.020 |
Why?
| Caffeine | 1 | 2006 | 64 | 0.020 |
Why?
| Peptide Mapping | 1 | 2005 | 22 | 0.020 |
Why?
| Air Movements | 1 | 2005 | 1 | 0.020 |
Why?
| Liver | 1 | 2011 | 1106 | 0.020 |
Why?
| Cell Cycle | 1 | 2006 | 226 | 0.020 |
Why?
| Quality Control | 1 | 2005 | 96 | 0.020 |
Why?
| Tumor Stem Cell Assay | 1 | 2004 | 17 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 372 | 0.010 |
Why?
| Tennessee | 1 | 2003 | 36 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2009 | 483 | 0.010 |
Why?
| HL-60 Cells | 1 | 2003 | 18 | 0.010 |
Why?
| Solubility | 1 | 2003 | 72 | 0.010 |
Why?
| Cyclin B | 1 | 2003 | 5 | 0.010 |
Why?
| Water | 1 | 2003 | 74 | 0.010 |
Why?
| Cyclin B1 | 1 | 2003 | 6 | 0.010 |
Why?
| CDC2 Protein Kinase | 1 | 2003 | 17 | 0.010 |
Why?
| Heat-Shock Proteins | 1 | 2003 | 105 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2004 | 1525 | 0.010 |
Why?
|
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|